Summary
The provided FDA label excerpts relate only to thyroid C-cell tumor risk (boxed warning/contraindications/precaution) and do not contain sufficient information to support or assess the majority of the cited claims (indication for weight loss, dosing duration, effectiveness metrics, adverse reactions like nausea/vomiting/constipation, gallbladder/pancreatitis, monitoring rationale, and insurance/patent/coverage statements).
Category Scores
Accurate Statements
None of the provided claims explicitly match the supplied label excerpts about thyroid C-cell tumor risk, contraindications (MTC/MEN 2), or monitoring/uncertainty.
No matching claims were provided in the list that explicitly correspond to the thyroid C-cell tumor warning content in Sections 5.1 and 13.1 or the boxed warning excerpt.
Unsupported Statements
Wegovy (semaglutide) is approved for long-term use for weight loss.
No supportive/contradicting language for indications or usage was provided in the supplied label excerpts.
Clinical trials followed patients for up to two years.
No clinical study duration information was provided in the supplied label excerpts (Section 14 not included).
The FDA label allows continued Wegovy treatment as long as the drug remains effective and side effects are tolerable.
No label language about continuation criteria was provided in the supplied excerpts.
Weight regain is common once Wegovy treatment ends.
No label language about weight regain after discontinuation was provided in the supplied excerpts.
In one study, participants regained about two-thirds of the lost weight within one year after stopping Wegovy.
No study-specific post-discontinuation outcomes or proportions were provided in the supplied excerpts.
Ongoing use appears necessary to maintain results from Wegovy.
No label language about maintenance requirements or necessity was provided in the supplied excerpts.
Wegovy shows larger and more sustained weight loss than most previous medications.
No comparative efficacy statements or previous medication comparisons were provided in the supplied excerpts.
Average weight loss with Wegovy is roughly 15% of body weight over 68 weeks.
No efficacy numbers or trial endpoints were provided in the supplied excerpts (Section 14 not included).
Many patients keep most of the weight loss as long as they continue Wegovy treatment.
No label language about proportion of patients maintaining weight loss with continued treatment was provided in the supplied excerpts.
Common side effects of long-term Wegovy use include nausea.
No adverse reaction frequency list or long-term adverse reaction data was provided in the supplied excerpts.
Common side effects of long-term Wegovy use include vomiting.
No adverse reaction frequency list or long-term adverse reaction data was provided in the supplied excerpts.
Common side effects of long-term Wegovy use include constipation.
No adverse reaction frequency list or long-term adverse reaction data was provided in the supplied excerpts.
Less common risks of long-term Wegovy use include gallbladder problems.
No gallbladder adverse event information was provided in the supplied excerpts.
Less common risks of long-term Wegovy use include a possible link to pancreatitis.
No pancreatitis adverse event information or causality language was provided in the supplied excerpts.
Ongoing monitoring is required for Wegovy because the drug has only been on the market since 2021.
No monitoring requirements or any rationale tied to market duration (2021) was provided in the supplied excerpts.
Many private insurance plans reimburse Wegovy for obesity when specific criteria are met.
No payer/coverage or reimbursement information was provided in the supplied label excerpts.
Medicare does not cover Wegovy for weight loss alone.
No Medicare coverage information was provided in the supplied label excerpts.
Coverage for Wegovy varies widely.
No coverage variability information was provided in the supplied label excerpts.
Patients often face high out-of-pocket costs if insurance denies coverage.
No cost/out-of-pocket guidance was provided in the supplied label excerpts.
The primary U.S. patent for semaglutide is set to expire in 2031.
No patent duration/protection information was provided in the supplied label excerpts.
Additional patents may extend protection until 2032.
No patent duration/protection information was provided in the supplied label excerpts.
Contradictions
Low
AI Statement
None of the provided claims were directly contradicted by the supplied label excerpts.
Label Reference
Not applicable
Important Omissions
Thyroid C-cell tumor risk statements from the FDA label (boxed warning and Section 5.1) were not included among the listed claims (even though the provided label excerpts specifically address this warning).
Importance:
High
Label contraindications related to personal/family history of MTC or MEN 2 were not reflected in any of the listed claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The response includes numerous weight-loss efficacy/maintenance, adverse event, monitoring, and coverage/patent claims that are not supported by the supplied FDA label excerpts. It also omits the specific boxed warning/contraindication content that is present in the supplied label excerpts, which could lead to incomplete risk communication.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Majority of claims are unsupported by the provided FDA label excerpts; key boxed warning/contraindication content present in the excerpts is omitted.
Suggested Improvement
Restrict claims to information present in the supplied prescribing information (e.g., boxed warning/Section 5.1 and related contraindications/monitoring uncertainty for thyroid C-cell tumors) and remove or qualify statements not supported by the included label sections (Sections 1, 2, 6, 8, 14, and payer/patent information were not provided).